Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

NIH 5OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interleukin-12 Subunit p35 × Lymphoid × Clear all
NCT02542124 2018-11-16

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Neumedicines Inc.

Phase 2 Unknown
10 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02544724 2016-08-03

NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

Neumedicines Inc.

Phase 2 Unknown
12 enrolled
Lymphoid

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡